

DB=PGPB; PLUR=YES; OP=ADJ

L11 (fish adj oil) same (antibod\$ or immunoglobulin\$ or immunosuppressive\$ or rapamycin\$) 417 L11

DB=DWPI; PLUR=YES; OP=ADJ

L10 (("DE 3781686G")!.ABPN1,NRPN.) .p22-p52. 1 L10

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L9 (fish adj oil) same (antibod\$ or immunoglobulin\$ or immunosuppressive\$ or rapamycin\$) 4 L9

DB=USPT; PLUR=YES; OP=ADJ

L8 L7 same (antibod\$ or immunoglobulin\$ or immunosuppressive\$ or rapamycin\$) 30 L8

L7 (fish adj oil) same (pharmaceutical or therapeutic) same (composition\$) 100 L7

L6 (rapamycin\$) and (kit\$) same (pharmaceutical or therap\$ or treat\$) same (immunosuppressiv\$) 22 L6

L5 (rapamycin\$) and (kit\$) same (pharmaceutical or therap\$ or treat\$) same (antibod\$) 115 L5

L4 (rapamycin\$) and (kit\$) same (pharmaceutical or therap\$ or treat\$) 516 L4

DB=PGPB; PLUR=YES; OP=ADJ

L3 11 51 L3

DB=USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L2 L1 25 L2

DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L1 (rapamycin\$) same (kit\$) same (pharmaceutical or therap\$ or treat\$) 76 L1

END OF SEARCH HISTORY



US 20040202650A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2004/0202650 A1****Gribben et al.**(43) **Pub. Date: Oct. 14, 2004**(54) **METHODS OF INHIBITING T CELL
PROLIFERATION OR IL-2 ACCUMULATION
WITH CTLA-4 SPECIFIC ANTIBODIES**(52) **U.S. Cl. 424/131.1; 424/144.1**(76) **Inventors: John G. Gribben, Brookline, MA
(US); Gordon J. Freeman, Brookline,
MA (US); Lee M. Nadler, Newton,
MA (US); Paul D. Rennert, Holliston,
MA (US); Cindy L. Jellis,
Londonderry, NH (US); Edward
Greenfield, Randolph, MA (US); Gary
S. Gray, Brookline, MA (US)****Correspondence Address:
LAHIVE & COCKFIELD, LLP.
28 STATE STREET
BOSTON, MA 02109 (US)**(21) **Appl. No.: 10/732,847**(22) **Filed: Dec. 9, 2003****Related U.S. Application Data**(62) **Division of application No. 08/253,783, filed on Jun.
3, 1994, now Pat. No. 6,719,972.****Publication Classification**(51) **Int. Cl.⁷ A61K 39/395**(57) **ABSTRACT**

Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e.g., for use in purging alloreactive T cells from donor bone marrow prior to bone marrow transplantation to inhibit graft versus host disease.

